Filer Snapshot

Aclaris Therapeutics, Inc.

CIK 0001557746. SEC filing timeline plus parsed ownership intelligence from 13F, 13D/G, and Forms 3/4/5 where available.

Entity type

Company

Total filings

849

Latest filing

28 Apr 2026

Industry

n/a

Filing-backed research brief

Start with the SEC data that changes for this CIK

Latest signal: SEC filing timeline only. Each card links back to the PortfolioSavvy page where the filing evidence is closest.

Go to filings Save page

Largest parsed holding

—

Populates from the latest parsed 13F information table.

Open holding

13D/G large stake

—

No recent parsed 13D/G stake row for this CIK.

Browse 13D/G

Save this filer page

Create a free account to keep this page in your watchlists. After verification, we will save it automatically and open your saved research list.

Create free account and save this filer Already have an account? Sign in and save it
Source: SEC filing 8-K

8-K filed on 28 Apr 2026 for CIK 0001557746.

View source filing
Listed symbols
ACRS on Nasdaq
At a glance Names, identifiers, and filing context for this profile. 1 identity field
Business address
701 Lee Road, Suite 103, Wayne, PA, 19087
EDGAR profile Static EDGAR fields kept behind disclosure so the main profile stays readable. 2 profile fields available
Incorporated in
DE
Fiscal year end
31 December

Filer intelligence

What SEC filings say about Aclaris Therapeutics, Inc.

A compact read of parsed XML filings. 13F, 13D/G, and Forms 3/4/5 are shown separately because they answer different ownership questions.

Save filer

SEC source mix

Counts show available parsed rows, not one combined ownership total.

No XML rows yet
13F portfolio No rows yet

Quarterly institutional portfolio holdings.

13D/G stakes No rows yet

Beneficial ownership and large-stake disclosures.

Forms 3/4/5 No rows yet

Officer, director, and 10% owner holdings or transactions.

No parsed ownership summary yet

We still show the SEC filing timeline below. The intelligence summary will populate when parsed 13F, 13D/G, or Forms 3/4/5 data exists for this CIK.

SEC filing record

CIK 0001557746 filing coverage

Start with this filing record, then use the linked ownership pages when parsed 13F, 13D/G, Forms 3/4/5, or facts data exists for this CIK.

SEC filings
849
First seen
10 Sep 2012
Latest filing
28 Apr 2026
Entity
Company

Observed form types

8-K 4 SCHEDULE 13G/A ARS DEFA14A DEF 14A SCHEDULE 13G 10-K 4/A 10-Q +31 more

CIK-linked evidence first

Aclaris Therapeutics, Inc. SEC filings 00461U105 holder history Open SEC filing index

Latest Filings

Showing the latest 12 of 849 SEC filings for Aclaris Therapeutics, Inc..

Open full filing history
4

4 filing

Filing date
27 Apr 2026
Reporting date
27 Apr 2026
SEC evidence
Open document Open filing
Next action
Verify source filing
SCHEDULE 13G/A File 005-89137

SCHEDULE 13G/A filing

Filing date
27 Apr 2026
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
ARS File 001-37581

ARS

Filing date
23 Apr 2026
Reporting date
31 Dec 2025
SEC evidence
Open document Open filing
Next action
Verify source filing
DEFA14A File 001-37581

DEFA14A

Filing date
23 Apr 2026
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
DEF 14A File 001-37581

DEF 14A

Filing date
23 Apr 2026
Reporting date
04 Jun 2026
Next action
Verify source filing
SCHEDULE 13G File 005-89137

SCHEDULE 13G filing

Filing date
07 Apr 2026
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
SCHEDULE 13G/A File 005-89137

SCHEDULE 13G/A filing

Filing date
26 Mar 2026
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
SCHEDULE 13G File 005-89137

SCHEDULE 13G filing

Filing date
17 Mar 2026
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
4

4 filing

Filing date
03 Mar 2026
Reporting date
01 Mar 2026
SEC evidence
Open document Open filing
Next action
Verify source filing
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .